Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections
Ruwen Böhm, Claudia Bulin, Vicki Waetzig, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 11, pp. 4421-4431
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Robert Morris, Rahinatu Ali, Feng Cheng
Current Drug Targets (2024) Vol. 25, Iss. 7, pp. 454-464
Closed Access | Times Cited: 9
Comparison of serious adverse effects of methylphenidate, atomoxetine and amphetamine in the treatment of ADHD: an adverse event analysis based on the FAERS database
Li‐Tzy Wu, Dan Zhao, Yue Lan, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Drugs Associated with Floppy Iris Syndrome: A Real-World Population-Based Study
Moiz Lakhani, Angela T.H. Kwan, Andrew Mihalache, et al.
American Journal of Ophthalmology (2025)
Closed Access | Times Cited: 1
Identification of Signal of Clindamycin Associated Renal Failure Acute: A Disproportionality Analysis
Faiza Javed, Anoop Kumar
Current Drug Safety (2023) Vol. 19, Iss. 1, pp. 123-128
Closed Access | Times Cited: 19
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
Afsaneh Shirani, Anne H. Cross, Olaf Stüve
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 6
Identification of novel signal of clobazam‐associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis
Akash Sharma, Anoop Kumar
Acta Neurologica Scandinavica (2022) Vol. 146, Iss. 5, pp. 623-627
Closed Access | Times Cited: 26
Adverse tumor events induced by ranitidine: an analysis based on the FAERS database
ManTing Liu, DongQiang Luo, JiaZhen Jiang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-13
Closed Access | Times Cited: 5
A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic
Justin Baroukhian, Kristina Seiffert-Sinha, Animesh A. Sinha
Frontiers in Immunology (2025) Vol. 15
Open Access
Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
Ziyang Wu, Pengxiang Zhou, Na He, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 21
A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
Yan Wu, Meihao Wei, Jing Zhang
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database
Jinhua Chen, Shi‐Jun Xu, Weijiang Yu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
The Safety Profile of Amiodarone Among Older Adults (age ≥ 75 years): A Pharmacovigilance Study from the FDA Data
Tsahi T. Lerman, Chen Gadot, Noam Greenberg, et al.
The American Journal of Medicine (2025)
Closed Access
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
Quanfeng Zhao, Pan Ma, Peishu Fu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 18
Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study
Kevin Pozsgai, Gergő Szűcs, Anikó Kőnig-Péter, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 18
Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
Hailong Li, Miao Zhang, Xue‐Feng Jiao, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
Feifei Wang, Bingfeng Zhou, Hongwei Sun, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database
Jie Li, Yilei Wang, Xiang Yang, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 8, pp. 1061-1067
Closed Access | Times Cited: 9
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Dehua Zhao, Xiaoqing Long, Jisheng Wang
BMC Pharmacology and Toxicology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Blind Spots in Therapy
Owais M. Aftab, Hamza N. Khan, Albert S Khouri
Ophthalmology Glaucoma (2024) Vol. 7, Iss. 5, pp. 485-490
Open Access | Times Cited: 3
Evaluation of link between COVID-19 adjacent spike in hydroxychloroquine use and increased reports of pemphigus: a disproportionality analysis of the FDA Adverse Event Reporting System
Justin Baroukhian, Kristina Seiffert-Sinha, Kristopher Attwood, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
Theodoros Soldatos, Sarah Kim, Stephan Schmidt, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 11, Iss. 5, pp. 540-555
Open Access | Times Cited: 15
Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System
Miao Zhang, Hailong Li, Liang Huang, et al.
European Journal of Pediatrics (2023) Vol. 182, Iss. 10, pp. 4655-4661
Closed Access | Times Cited: 8
Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
Wei Wei, Li Chen, Hui Zhou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data
Tsahi T. Lerman, Noam Greenberg, Boris Fishman, et al.
International Journal of Cardiology (2023) Vol. 397, pp. 131613-131613
Closed Access | Times Cited: 8
Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
Yi Liu, Yanguo Liu, Rongrong Fan, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top